PharmaEssentia Completes Patient Enrollment for Phase 2b EXCEED-ET Trial in Essential Thrombocythemia and Phase 3b ECLIPSE-PV Trial in Polycythemia Vera
“Myeloproliferative neoplasms, including ET and PV, are chronic blood diseases [...]
Micro Medical Solutions | Achieves Milestone with 200th Enrollment in HEAL Registry
reg Sullivan, CEO of Micro Medical Solutions. “This milestone is [...]
Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.
The VenusP-Valve PROTEUS STUDY, abbreviated from Evaluation of the PerfoRmance [...]
Pfizer Reports | ELREXFIO ™ Shows Median Overall Survival of More Than Two Years in People with Relapsed or Refractory Multiple Myeloma
“These compelling overall survival data support the clinical benefit ELREXFIO [...]
Updated Phase 2 CAPTIVATE Study Results
“After more than five years, the CAPTIVATE study findings confirm [...]
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease | Presented at the European Hematology Association (EHA) Annual Congress
“These data confirm the observations from our prior clinical readouts [...]
Innovent Biologics Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
Dr. Hui Zhou, Senior Vice President of Innovent, stated: “IBI363, [...]
Positive 6 Month Results from CroíValve’s TANDEM I Study to Treat Tricuspid Regurgitation Presented at New York Valves 2024
Favorable patient outcomes from the TANDEM I first-in-human clinical trial [...]
Deciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The Lancet
Deciphera Pharmaceuticals notes the article titled “Vimseltinib versus placebo for [...]
Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a [...]